Solid pharmaceutical drugs are known to have different physical properties, such as solubility, bioavailability and stability, depending on their crystal form. This is why these drugs are productized in specific crystalline forms. However, solid pharmaceutical drugs are subject to processing such as grinding, drying, and tableting during manufacturing (formulation), which may lead to polymorphic transition and amorphization. Because amorphous components have physical properties different from crystalline components, confirming the presence/absence of amorphous substances and crystallinity is important in the production of solid pharmaceutical drugs.
We introduce a method for determining the presence/absence of an amorphous substance by differential scanning calorimetry (DSC) and powder X-ray diffraction measurement (XRD). In addition, we also introduce the crystallinity calculation method by the multiple peaks decomposition method for powder X-ray diffraction measurement.
Advanced state-of-the-art high-resolution XRD system powered by Guidance expert system software
Highly versatile multipurpose X-ray diffractometer with built-in intelligent guidance
New 6th-generation general purpose benchtop XRD system for phase i.d and phase quantification
Compact X-ray diffractometer for quality control of materials that is easy to use and is ideal for routine work
Laboratory micro-spot XRD residual stress analysis with both iso- and side-inclination methods
Windows®-based software suite for Rigaku's X-ray diffractometers